Revance Therapeutics, Inc. (RTI.F)
- Previous Close
3.0000 - Open
3.0600 - Bid 3.1400 x --
- Ask 3.2800 x --
- Day's Range
3.0600 - 3.1200 - 52 Week Range
3.0000 - 33.2000 - Volume
520 - Avg. Volume
42 - Market Cap (intraday)
330.299M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-3.5700 - Earnings Date May 6, 2024 - May 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.78
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
www.revance.comRecent News: RTI.F
Performance Overview: RTI.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RTI.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RTI.F
Valuation Measures
Market Cap
330.30M
Enterprise Value
539.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.21
Price/Book (mrq)
--
Enterprise Value/Revenue
2.31
Enterprise Value/EBITDA
-1.86
Financial Highlights
Profitability and Income Statement
Profit Margin
-138.43%
Return on Assets (ttm)
-26.02%
Return on Equity (ttm)
--
Revenue (ttm)
234.04M
Net Income Avi to Common (ttm)
-323.99M
Diluted EPS (ttm)
-3.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
253.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-134.99M
Research Analysis: RTI.F
Company Insights: RTI.F
RTI.F does not have Company Insights